Offer - Urjas Oil for just Rs 1 X
Pramirol 0.5 Tablet is a prescription drug, available for use as Tablet. Parkinson's Disease are some of its major therapeutic uses. Other than this, Pramirol 0.5 Tablet has some other therapeutic uses, which have been discussed ahead.
Medical history of the patient along with age and gender determines the dosage of Pramirol 0.5 Tablet. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. For detailed information on this, read through the dosage section.
Apart from the aforementioned side effects, Pramirol 0.5 Tablet can also lead to other problems, which have been listed below. Such side effects of Pramirol 0.5 Tablet normally do not last long and go away once the treatment is completed. Please speak with your doctor if these side effects worsen or persist for a longer duration.
In addition, Pramirol 0.5 Tablet's effect is Moderate during pregnancy and Severe for lactating mothers. In addition, Pramirol 0.5 Tablet's effects on the liver, heart and kidney are discussed below in the Pramirol 0.5 Tablet related warnings section.
Individuals suffering from medical conditions like Schizophrenia, Heart Disease, Kidney Disease must refrain from the use of Pramirol 0.5 Tablet since this can cause severe adverse effects.
Additionally, Pramirol 0.5 Tablet may also adversely react with other medicines. See below for a complete list.
You should also be aware that Pramirol 0.5 Tablet is not safe while driving, and is not addiction.
Pramirol 0.5 Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Pramirol 0.5 Tablet safe for pregnant women?
Pramirol can have harmful effects in pregnant women. If you experience any discomfort after using Pramirol, then discontinue the use and take your doctor's advice.
Is the use of Pramirol 0.5 Tablet safe during breastfeeding?
Taking Pramirol may lead to serious side effects if you are breastfeeding. Pramirol should not be taken by breastfeeding women unless prescribed by the doctor.
What is the effect of Pramirol 0.5 Tablet on the Kidneys?
Pramirol rarely harms the kidneys.
What is the effect of Pramirol 0.5 Tablet on the Liver?
Pramirol does not damage the liver.
What is the effect of Pramirol 0.5 Tablet on the Heart?
Very few cases of side effects of Pramirol on the heart have been reported.
If you are suffering from any of the following diseases, you should not take Pramirol 0.5 Tablet unless your doctor advises you to do so -
Is this Pramirol 0.5 Tablet habit forming or addictive?
No, there is no any evidence that Pramirol 0.5 Tablet is addictive.
Is it safe to drive or operate heavy machinery when consuming?
After taking Pramirol 0.5 Tablet you may feel sleepy. So it is not advised to perform these activities.
Is it safe?
Yes, Pramirol 0.5 Tablet is safe but you must consult your doctor before taking it.
Is it able to treat mental disorders?
Yes, taking Pramirol 0.5 Tablet can treat mental disorders.
Interaction between Food and Pramirol 0.5 Tablet
Some foods when eaten with Pramirol 0.5 Tablet can alter the onset of actions. Discuss this with your doctor.
Interaction between Alcohol and Pramirol 0.5 Tablet
Taking Pramirol 0.5 Tablet with alcohol can have severely harmful effects on your health.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Mirapex® (pramipexole dihydrochloride)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1043-1044
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 430-431